1. Home
  2. VNT vs BLCO Comparison

VNT vs BLCO Comparison

Compare VNT & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vontier Corporation

VNT

Vontier Corporation

HOLD

Current Price

$29.21

Market Cap

5.0B

Sector

Industrials

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$15.09

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VNT
BLCO
Founded
2019
1853
Country
United States
Canada
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Ophthalmic Goods
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
5.9B
IPO Year
2020
2022

Fundamental Metrics

Financial Performance
Metric
VNT
BLCO
Price
$29.21
$15.09
Analyst Decision
Buy
Buy
Analyst Count
9
11
Target Price
$46.89
$18.45
AVG Volume (30 Days)
2.0M
412.2K
Earning Date
05-07-2026
04-29-2026
Dividend Yield
0.29%
N/A
EPS Growth
0.36
N/A
EPS
0.66
N/A
Revenue
$3,075,600,000.00
$5,101,000,000.00
Revenue This Year
$2.39
$8.65
Revenue Next Year
$4.19
$5.59
P/E Ratio
$43.44
N/A
Revenue Growth
3.24
6.47
52 Week Low
$27.25
$11.44
52 Week High
$48.20
$18.92

Technical Indicators

Market Signals
Indicator
VNT
BLCO
Relative Strength Index (RSI) 44.65 40.13
Support Level $27.47 $14.55
Resistance Level $29.74 $15.57
Average True Range (ATR) 0.78 0.38
MACD 0.31 -0.02
Stochastic Oscillator 74.63 24.58

Price Performance

Historical Comparison
VNT
BLCO

About VNT Vontier Corporation

Vontier, spun off from Fortive in 2020, is an industrial technology company with a portfolio of transportation and mobility solutions. The company offers a wide array of products and services, including fueling equipment, sensors, point-of-sale and payment systems, telematics, and equipment used by vehicle mechanics and technicians. Vontier generated approximately $3.1 billion in sales in 2025.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: